@article{29291c834aa845008bae9fb0dc80422b,
title = "GRADE guidelines: 22. The GRADE approach for tests and strategies—from test accuracy to patient-important outcomes and recommendations",
abstract = "Objectives: This article describes the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group's framework of moving from test accuracy to patient or population-important outcomes. We focus on the common scenario when studies directly evaluating the effect of diagnostic and other tests or strategies on health outcomes are not available or are not providing the best available evidence. Study Design and Setting: Using practical examples, we explored how guideline developers and other decision makers can use information from test accuracy to develop a recommendation by linking evidence that addresses downstream consequences. Guideline panels should develop an analytic framework that summarizes the actions that follow from applying a test and the consequences. Results: We describe GRADE's current thinking about the overall certainty of the evidence (also known as quality of the evidence or confidence in the estimates) arising from consideration of the often complex pathways that involve multiple tests and management options. Each link in the evidence can—and often does—lower the overall certainty of the evidence required to formulate recommendations and make decisions about tests. The frequency with which an outcome occurs and its importance will influence whether or not a particular step in the linked evidence is critical to decision-making. Conclusions: Overall certainty may be expressed by the weakest critical step in the linked evidence. The linked approach to addressing optimal testing will often require the use of decision analytic approaches. We present an example that involves decision modeling in a GRADE Evidence to Decision framework for cervical cancer screening. However, because resources and time of guideline developers may be limited, we describe alternative, pragmatic strategies for developing recommendations addressing test use.",
keywords = "Diagnosis, Frameworks, GRADE, Guidelines, Recommendations, Systematic reviews, Tests",
author = "Sch{\"u}nemann, {Holger J.} and Mustafa, {Reem A.} and Jan Brozek and Nancy Santesso and Bossuyt, {Patrick M.} and Steingart, {Karen R.} and Mariska Leeflang and Stefan Lange and Tommaso Trenti and Miranda Langendam and Rob Scholten and Lotty Hooft and Murad, {Mohammad Hassan} and Roman Jaeschke and Anne Rutjes and Jasvinder Singh and Mark Helfand and Paul Glasziou and Ingrid Arevalo-Rodriguez and Akl, {Elie A.} and Deeks, {Jonathan J.} and Guyatt, {Gordon H.}",
note = "Funding Information: Conflict of interest statement: The authors are members of the GRADE Working Group. J.A.S. has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC and the American College of Rheumatology. J.A.S. serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c) (3) entity. J.S. is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology, and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. J.S. is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. The other authors declared no financial conflict of interest. Funding Information: This work was partially funded by a European Community's Sixth Framework Programme ( FP6/2001-2006 ) “The human factor, Mobility and Marie Curie Actions Scientist Reintegration” IGR 42192 – (“GRADE” to Dr. Sch{\"u}nemann), the European Commission's Seventh Framework Programme ( FP7/2007-2013 ) under grant agreement °258583 (DECIDE project), and the German Insurance Fund. Sole responsibility lies with the authors, and the European Commission is not responsible for any use that may be made of the information contained therein. The systematic reviews describing the HPV/VIA example were supported by grants to HJS and NS from the World Health Organization but the work presented here reflects the interpretation of the authors not of the World Health Organization. We would like to thank the many individuals and organizations who have contributed to the progress of the GRADE approach through funding of meetings and feedback on the work described in this article. The authors particularly thank Andrew D. Oxman who contributed significantly to earlier discussions and the shaping of the approach. Funding Information: This work was partially funded by a European Community's Sixth Framework Programme (FP6/2001-2006) ?The human factor, Mobility and Marie Curie Actions Scientist Reintegration? IGR 42192 ? (?GRADE? to Dr. Sch?nemann), the European Commission's Seventh Framework Programme (FP7/2007-2013) under grant agreement ?258583 (DECIDE project), and the German Insurance Fund. Sole responsibility lies with the authors, and the European Commission is not responsible for any use that may be made of the information contained therein. The systematic reviews describing the HPV/VIA example were supported by grants to HJS and NS from the World Health Organization but the work presented here reflects the interpretation of the authors not of the World Health Organization. We would like to thank the many individuals and organizations who have contributed to the progress of the GRADE approach through funding of meetings and feedback on the work described in this article. The authors particularly thank Andrew D. Oxman who contributed significantly to earlier discussions and the shaping of the approach. Conflict of interest statement: The authors are members of the GRADE Working Group. J.A.S. has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC and the American College of Rheumatology. J.A.S. serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c) (3) entity. J.S. is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology, and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. J.S. is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. The other authors declared no financial conflict of interest. Publisher Copyright: {\textcopyright} 2019",
year = "2019",
month = jul,
day = "1",
doi = "10.1016/j.jclinepi.2019.02.003",
language = "English",
volume = "111",
pages = "69--82",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier USA",
}